Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614323 | 1.00 | ADRB2 (0.56) | ADRB2ADRB1ADRB3CASP3CASP6 | |
| SCHEMBL4614316 | 1.00 | ADRB2 (0.56) | ADRB2ADRB1ADRB3CASP3CASP6 | |
| SCHEMBL4613366 | 1.00 | ADRB2 (0.56) | ADRB2ADRB1ADRB3CASP3CASP6 | |
| SCHEMBL4857137 | 0.94 | ADRB2 (0.62) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL4857134 | 0.94 | ADRB2 (0.62) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL4616405 | 0.93 | ADRB2 (0.53) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL5682922 | 0.93 | ADRB2 (0.53) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL4616404 | 0.93 | ADRB2 (0.53) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL5682914 | 0.93 | ADRB2 (0.53) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL5681758 | 0.93 | ADRB2 (0.53) | ADRB2ADRB1ADRB3CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633714-B1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-7067541-B2 | 2-amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1633714-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20050004182-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004108675-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004182-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PAH, AADAT, IL4I1 | ADRB2 176/4885ADRB1 250/4885ADRB3 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.